BERLIN (Reuters) – German health technology company Siemens Healthineers raised its full-year sales and profit forecast on Monday, as the global COVID-19 pandemic continues to drive demand for its rapid antigen tests.
The medical technology group now expects sales to grow 14%-17% in the year to September, up from a previous forecast for a rise of 8%-12%. Adjusted basic earnings per share are seen at 1.90-2.05 euros versus an earlier forecast of 1.63-1.82 euros.
Siemens Healthineers said it now expected rapid antigen test revenues of around 750 million euros in 2021, up from 300-350 million previously forecast.
Sales in the January-March period, Siemens Healthineers’ fiscal second quarter, rose to 7.6% to 3.965 billion euros ($4.77 billion), while net income increased 8% to 447 million euros.
($1 = 0.8319 euros)
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.